General
Four Clear Messages from Bristol-Myers Squibb FCPA Enforcement Action
The SEC’s FCPA enforcement action for $14.6 million against Bristol-Myers Squibb (“BMS") in China provides a textbook example of how things can go wrong in China. For the compliance practitioner (as well as CEO and senior executives) in the pharmaceutical and medical device industries, the BMS